A new study involving elamipretide was published on July 14, 2026. The publication is titled "Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice." It appeared in the journal Neurochemical Research.
The study examines elamipretide, also known as SS-31, in combination with nicotinamide mononucleotide, referred to as NMN. According to the title, the research focuses on a target called TREM2 in the context of post-ischemic brain injury in a mouse model.
This entry reflects only the publication record as listed, including its title, journal, and date. No specific findings, results, or conclusions from the study have been provided beyond what is stated in the title itself. Readers interested in the full scope of the research, including methodology and outcomes, should consult the original publication directly.
Elamipretide is currently classified as an approved compound. This publication represents ongoing scientific interest in its potential applications, as documented through peer-reviewed research channels. For more background on elamipretide, readers can refer to the compound overview.